Ipx-179 //free\\ Guide

In 2020, the pharmaceutical company, Invelta Biosciences, announced the initiation of a Phase I clinical trial of IPX-179 in patients with early-stage Parkinson's disease. The trial, which was designed to evaluate the safety and tolerability of the compound, enrolled 24 patients who received either a single dose or multiple doses of IPX-179 over a period of 28 days.